(Q84027466)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541730%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

title

[Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541730%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

D Jullien

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541730%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

1 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541730%20AND%20SRC:MED&resulttype=core&format=json

Annales de dermatologie et de vénéréologie

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541730%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

139 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541730%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

S58-67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541730%20AND%20SRC:MED&resulttype=core&format=json

[Immunogenicity of therapeutic antibodies].

30 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

CD4 antibody treatment of severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Adalimumab real-world dosage pattern and predictors of weekly dosing: patients with Crohn's disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Etanercept and venous thromboembolism: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

TNF alpha antagonist therapy and safety monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Drug-induced systemic lupus erythematosus associated with etanercept therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Anti-TNF-alpha-induced systemic lupus syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis but do not necessarily predict treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0151-9638%2812%2970112-6

7 January 2021

10.1016/S0151-9638(12)70112-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541730%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference